{"id":6812,"date":"2025-09-12T23:04:37","date_gmt":"2025-09-12T23:04:37","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/09\/12\/fda-may-abandon-drug-advisory-committee-reviews\/"},"modified":"2025-09-12T23:04:37","modified_gmt":"2025-09-12T23:04:37","slug":"fda-may-abandon-drug-advisory-committee-reviews","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/09\/12\/fda-may-abandon-drug-advisory-committee-reviews\/","title":{"rendered":"FDA leaders moving to abandon advisory committee reviews of specific new drugs"},"content":{"rendered":"<p>    FDA leaders moving to abandon advisory committee reviews of specific new drugs<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency\u2019s decisions from public scrutiny.<\/p>\n<p>The agency \u201cwould like to get away\u201d from assembling panels of experts to examine and vote on individual drugs, because \u201cI don\u2019t think they\u2019re needed,\u201d said George Tidmarsh, head of the FDA\u2019s Center for Drug Evaluation and Research. He relayed the message Tuesday at a meeting of health care product makers and Wednesday to an FDA advocacy group.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/09\/12\/fda-may-abandon-drug-advisory-committee-reviews\/?utm_campaign=rss\">Read the rest\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Arthur Allen \u2014 KFF Health News<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/09\/12\/fda-may-abandon-drug-advisory-committee-reviews\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA leaders moving to abandon advisory committee reviews of specific new drugs FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency\u2019s decisions from public scrutiny. The agency \u201cwould like to get away\u201d from assembling panels [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2154,2146,2176,2155,2144],"tags":[2150],"class_list":["post-6812","post","type-post","status-publish","format-standard","hentry","category-biotechnology","category-fda","category-pharma","category-pharmaceuticals","category-politics","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6812"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=6812"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6812\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=6812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=6812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=6812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}